Skip to Primary Navigation

Skip to main content

AstraZeneca faces US class action lawsuit amidst China regulatory probes

A general view of signage at Astra Zeneca's vaccine plant at Speke on February 05, 2025 in Liverpool, England.
Photo: Christopher Furlong/Getty Images

Jean Hurley

1 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

The lawsuit claims that UK’s largest listed company misled shareholders in connection with investigations by the Chinese government.

AstraZeneca PLC, the British-Swedish pharmaceutical giant, is facing a securities class action lawsuit in the US. The action alleges that the company misled investors about its business practices in China.

The lawsuit, filed in the US District Court for the Central District of California, claims that AstraZeneca made false and

, , , , , ,

Get full access, free for a month

Start your 28-day free trial to continue reading and access
all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience